First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerLeora Horn, Stephen V. Liu, Florian Huemer et al.|New England Journal of Medicine|2018Cited by 3.5k
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trialMary O’Brien, Solange Peters, Luis Paz‐Ares et al.|The Lancet Oncology|2022Cited by 738
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension studyMartin Reck, Stephen V. Liu, Rafał Dziadziuszko et al.|Lung Cancer|2024Cited by 66